A detailed history of Ever Source Wealth Advisors, LLC transactions in Collegium Pharmaceutical, Inc stock. As of the latest transaction made, Ever Source Wealth Advisors, LLC holds 318 shares of COLL stock, worth $10,188. This represents 0.0% of its overall portfolio holdings.

Number of Shares
318
Previous 676 52.96%
Holding current value
$10,188
Previous $26,000 53.85%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Jun 11, 2024

SELL
$31.23 - $40.91 $11,180 - $14,645
-358 Reduced 52.96%
318 $12,000
Q4 2023

Feb 09, 2024

BUY
$21.16 - $30.8 $8,104 - $11,796
383 Added 130.72%
676 $20,000
Q1 2023

May 11, 2023

BUY
$23.0 - $29.88 $2,898 - $3,764
126 Added 75.45%
293 $7,000
Q3 2022

Nov 07, 2022

BUY
$15.46 - $20.1 $2,581 - $3,356
167 New
167 $3,000
Q1 2022

May 25, 2022

SELL
$17.2 - $22.5 $3,268 - $4,275
-190 Closed
0 $0
Q4 2021

Feb 07, 2022

BUY
$17.5 - $21.35 $3,325 - $4,056
190 New
190 $4,000

Others Institutions Holding COLL

About COLLEGIUM PHARMACEUTICAL, INC


  • Ticker COLL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 34,126,200
  • Market Cap $1.09B
  • Description
  • Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ...
More about COLL
Track This Portfolio

Track Ever Source Wealth Advisors, LLC Portfolio

Follow Ever Source Wealth Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ever Source Wealth Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ever Source Wealth Advisors, LLC with notifications on news.